Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Arvinas, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Arvinas, Inc. (ARVN) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. (“Arvinas” or “the Company”) (NASDAQ: ARVN). Investors who purchased Arvinas securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Arvinas has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On May 1, 2025, Arvinas issued a press release announcing that the Company and its development partners at Pfizer had “removed plans for a Phase 3 first-line combination trial with atirmociclib, as well as the planned Phase 3 second-line combination trial with a CDK4/6 inhibitor, from our joint development plan.” Arvinas’s Chief Executive Officer said that the “decision was made following a review of the totality of emerging information, including external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation.” Arvinas also “[a]nnounced a reduction in workforce of approximately one-third across the Company to streamline operations across the organization and enable the efficient progression of the Company’s portfolio”, advising that “[t]he reduction is planned to be completed in the second quarter of 2025.” On this news, Arvina’s stock price fell $2.39 per share, or 24.84%, to close at $7.23 per share on May 1, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Arvinas securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
How Did Arvinas, Inc. (ARVN) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”